Tovetumab

立即咨询

Tovetumab

本产品不向个人销售，仅用作科学研究，不用于任何人体实验及非科研性质的动物实验。

CAS NO:

1243266-04-7

MEDI-575

Tovetumab (MEDI-575) 是一种抗PDGFRα单克隆抗体，可选择性的阻断 PDGFRα 信号转导。Tovetumab 可用于胶质母细胞瘤和非小细胞肺癌 (NSCLC) 的研究。

生物活性

Tovetumab (MEDI-575) is an anti-PDGFRαmonoclonal antibody that selectively blocks thePDGFRαsignal transduction. Tovetumab can be used in the research of glioblastoma and non-small cell lungcancer(NSCLC)^[1]^[2].

IC₅₀& Target^[1]

PDGFRα

体外研究
(In Vitro)

Tovetumab (10-100 nM, 1-2 h) binds to PDGFRα on H1703 cells (determined by Alexa647-labeled tovetumab)^[1].
Tovetumab (0.001-10 nM, 10 min) inhibits ligand-induced phosphorylation of human PDGFRα in MG-63 cells^[2].
Tovetumab (0.001-100 nM, 72 h ) inhibits Ligand-induced proliferation of cancer-associated fibroblasts (CAFs)^[2].

体内研究
(In Vivo)

Tovetumab (0.6-60 mg/kg, i.v.) blocks the PDGFRα-mediated elimination of PDGF-AA, leading to an increase in circulating PDGF-AA level in Cynomolgus monkeys^[1].
Tovetumab (10 mg/kg, i.p., twice a week) inhibits tumor growth in U118 glioma xenografts^[2].

Animal Model:	Cynomolgus monkey^[1]
Dosage:	0.6, 6.0, and 60 mg/kg
Administration:	Intravenous injection (i.v.)
Result:	Induced >100- fold increases in circulating concentrations of PDGF-AA.

Animal Model:	U118 glioma xenografts (CB17 SCID)^[2]
Dosage:	10 mg/kg
Administration:	Intraperitoneal injection (i.p.), twice per week.
Result:	Produced 101% inhibition of tumor growth.

Clinical Trial

性状

Liquid

CAS 号

1243266-04-7

运输条件

Room temperature in continental US; may vary elsewhere.

储存方式

Please store the product under the recommended conditions in the Certificate of Analysis.